Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Marimastat may stop the growth of non-small cell lung cancer by stopping blood
flow to the tumor.
PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of
marimastat in treating patients who have residual stage III non-small cell lung cancer.